Peripheral T-cell Lymphoma Not Otherwise Specified
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma Not Otherwise Specified.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]
Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating adding duvelisib or CC-486 to standard therapy for several peripheral T-cell lymphomas has been suspended.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update for AUTO4 in TRBC1-positive T-cell lymphomas shows Phase 1/2 results with the study terminated and results posted.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study i…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas [Phase 1, Phase 2]
This is a completed Phase 1/2 clinical trial from MD Anderson evaluating AFM13 and AFM13-NK in patients with recurrent or refractory CD30-po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating durvalumab with or without lenalidomide in patients with relapsed or refractory cutaneous or periph…
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas [Phase 2]
An open-label Phase 2 trial evaluating nanatinostat plus valganciclovir in EBV-positive relapsed/refractory lymphomas has been terminated, w…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH [Phase 2]
Phase 2 trial of daratumumab with gemcitabine, dexamethasone, and cisplatin in relapsed/refractory CD38+ peripheral T-cell lymphoma subtypes…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating combination chemotherapy with lenalidomide in newly diagnosed peripheral T-cell lymphoma (multiple subtypes) ha…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma [Phase 2]
A completed Phase 2 study evaluating the combination of bortezomib and panobinostat in relapsed or refractory peripheral T-cell lymphomas an…